Abstract. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression, primarily at the posttranscriptional level. Growing evidence suggests that miRNAs function as oncogenes or tumor suppressors in human cancers. The down-regulation of miR-145 has been reported in many types of human cancer, including prostate cancer (PC), suggesting that miR-145 functions as a tumor suppressor. Using the PC cell lines, PC3 and DU145, gain-of-function assays revealed that miR-145 transfection inhibited cell proliferation, migration and invasion. Fascin homolog 1 (FSCN1), an actin-bundling protein, is a candidate target gene of miR-145 based on genome-wide gene expression analysis. A luciferase reporter assay showed a significantly decreased signal at two miR-145 target sites at the 3'UTR of FSCN1, suggesting that miR-145 directly regulates FSCN1. In FSCN1 loss-of-function assays, cell growth, migration and invasion were all inhibited, implying that FSCN1 is associated with the progression of PC. The identification of tumor suppressive miRNAs and their target genes could provide new insights into the potential mechanisms of prostate carcinogenesis.
Introduction
Prostate cancer (PC) remains one of the most prevalent cancers and a major cause of morbidity and mortality in the western world (1) (2) (3) (4) . In 2007, ~220,000 new patients were diagnosed with PC and ~27,000 cancer-related deaths were reported (5) . Disease progression and the development of hormone refractory disease remain major causes of cancerrelated death. In order to significantly alter the disease course, improvements should be made in the understanding, diagnosis, and treatment of aggressive forms of metastatic PC.
MicroRNAs (miRNAs) are small, non-coding RNAs with a length of ~22 nucleotides. They regulate gene expression by promoting mRNA cleavage and at the post-transcriptional level, by translational suppression (6) . They play important roles in various biological and metabolic processes, including development, differentiation, signal transduction, cell maintenance and cancer (6, 7) . Bioinformatic predictions indicate that miRNAs regulate >30% of the protein coding genes (8) . It is estimated that ~1,000 miRNAs exist in the vertebrate genome. So far, 1,048 human miRNAs have been registered in miRBase release 16 .0 (http://microrna.sanger.ac.uk/).
An important role for miRNAs in the development of cancer has emerged over the years. miRNAs are aberrantly expressed in many human cancers, and they can function as oncogenes or tumor suppressors. Up-regulated miRNAs can function as oncogenes by negatively regulating tumor suppressor genes, while down-regulated miRNAs can act as tumor suppressors, inhibiting cancers by regulating oncogenes. A growing body of evidence indicates that unique miRNA expression profiles are associated with particular cancers. These profiles could serve as useful biomarkers for the diagnosis and prognosis of disease (9, 10) . Studies have been carried out for the purpose of identifying specific miRNA alterations in various cancers, including PC (11) (12) (13) (14) (15) (16) .
miR-145 has frequently been reported to be down-regulated in cancers, including prostate (17) , bladder (18) , colon (19) , ovary (20) and esophageal cancer (21) , as well as B-cell malignancies (22) . miR-145 is located on chromosome 5q32-33 within a 4.09 kb region (http://microrna.sanger.ac.uk/). Of interest, 5q31.1 is a well-known fragile site in the human genome (http://www.genenames.org/) and is often deleted in cancers. Increasing evidence indicates that miR-145 acts as a tumor suppressive miRNA which inhibits cell growth, invasion and migration in cancer cells (23) .
While data suggest that miR-145 plays a role in PC, there is limited knowledge of its targets. In this study, we focused on the target identification of miR-145 in PC, based on gene expression analysis of miR-145 transfectants. We demonstrate that miR-145 targets fascin homolog 1 (FSCN1) and that silencing FSCN1 reveals its function as an oncogene in PC.
Materials and methods
Cell lines and cell culture. The human PC cell lines, PC3 and DU145, were obtained from the American Type Culture Collection (Manassas, VA, USA). The PC cell lines were cultured in monolayers in RPMI-1640 medium supplemented with 10% fetal bovine serum, and maintained in an incubator with a humidified atmosphere of 95% air and 5% CO 2 at 37˚C.
RNA isolation. Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. RNA concentrations were determined spectrophotometrically, and molecular integrity was checked by gel electrophoresis. RNA quality was confirmed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).
Normal prostate RNAs were purchased as follows: Prostate-1 (Clontech Human Prostate Total RNA, no. 636550) and prostate-2 (Biochain Total RNA-Human Adult Normal Tissue, no. R1234201-50).
Mature miRNA transfection. Mature miRNA molecules, Pre-miR™ miRNA Precursors, and a negative control (hsamiR-145; P/N: AM17100 and negative control miRNA; P/N: AM17111; Applied Biosystems, Foster City, CA, USA) were incubated with Opti-MEM (Invitrogen) and Lipofectamine™ RNAiMax reagent (Invitrogen) as described previously (24) . We first confirmed the transfection efficiency of Pre-miR in the cell lines based on the down-regulation of PTK9 mRNA by transfection with miR-1 (as recommended by the manufacturer). Under our experimental conditions, the efficiency with which miRNA was transfected into PC cells was similar to our previous experiments and sufficient for experimental analysis.
Cell proliferation, migration and invasion assays. Cells were transfected with 10 nM miRNA by reverse transfection and plated in 96-well plates at 3x10 3 cells per well. After 72 h, cell proliferation was determined by the XTT assay, using the Cell Proliferation Kit II (Roche Molecular Biochemicals, Germany) as described previously (21, 25) . Triplicate wells were measured for cell viability in each treatment group. Cell migration activity was evaluated by wound-healing assays. Cells were plated in six-well dishes, and the cell monolayer was scraped using a micropipette tip. The initial gap width (0 h) and the residual gap width, 24 h after wounding, were calculated from photomicrographs as described previously (18, 21) . A cell invasion assay was carried out using modified Boyden chambers containing transwell-precoated Matrigel membrane filter inserts with 8-μm pores in 24-well tissue culture plates (BD Biosciences, Bedford, MA, USA), as described previously (18, 21) . All experiments were performed in triplicate.
Target gene search for miR-145. In order to identify the target genes of miR-145 in the PC cell lines, PC3 and DU145, we performed genome-wide screening using miR-145 transfectants compared to the miRNA-negative control transfectants. Oligo Microarray Human 44K (Agilent Technologies) was used for expression profiling in miR-145-transfected PC3 and DU145 cells in comparison to miRnegative-control transfectants, as described previously (18, 21, 25) . Briefly, hybridization and washing steps were performed as described previously (26) . The arrays were scanned using a Packard GSI Lumonics ScanArray 4000 (Perkin-Elmer, Boston, MA, USA). The data obtained were analyzed by means of DNASIS array software (Hitachi Software Engineering, Tokyo, Japan), which converted the signal intensity for each spot into text format. The log 2 ratios of the median subtracted background intensities were analyzed. Data from each microarray study were treated with a global normalization method as described previously (26) .
The predicted target genes and their conserved miRNA binding site seed regions were investigated using TargetScan (release 5.1, http://www.targetscan.org/). The sequences of the predicted mature miRNAs were confirmed using miRBase (release 16.0, http://microrna.sanger.ac.uk/).
Real-time quantitative RT-PCR.
First-strand cDNA was synthesized from 1 μg total RNA using random primers and the Reverse Transcription (RT) System (Promega, Tokyo, Japan). Gene-specific PCR products were assayed continuously using a 7900-HT Real-Time PCR System according to the manufacturer's instructions. The initial PCR step consisted of a 10-min hold at 95˚C, followed by 40 cycles of 15-sec denaturation at 95˚C and 1-min annealing/extension at 63˚C. TaqMan ® probes and primers for FSCN1 (P/N: Hs00979631_g1) were used (Assay-On-Demand Gene Expression Products; Applied Biosystems). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (A/N: NM_002046) or 18S (A/N: NR_003286) was used as the internal control (Assay-On-Demand Gene Expression Products; Applied Biosystems). The expression levels of miR-145 (P/N: 4427975) were analyzed by TaqMan quantitative real-time PCR (TaqMan ® MicroRNA Assay; Applied Biosystems) and normalized to RNU6B (A/N: K03099). All reactions were performed in triplicate, and included negative control reactions that lacked cDNA.
Immunoblotting. Cells were harvested 72 h after transfection. Protein lysates (50 μg) were separated by NuPAGE on a 4-12% bis-Tris gel (Invitrogen) and transferred onto PVDF membranes. Immunoblotting was performed with diluted (1:100) monoclonal FSCN1 antibody (ab49815, Abcam, Cambridge, UK), with GAPDH antibody (MAB374; Chemicon, Temecula, CA, USA) used as the internal control. The membrane was washed and then incubated with goat anti-mouse IgG (H+L)-HRP conjugate (Bio-Rad, Hercules, CA). Specific complexes were visualized by echochemiluminescence (GE Healthcare Bio-Sciences, Princeton, NJ).
Plasmid construction and dual-luciferase assay. miR-145
target sequences were chemically synthesized (Takara, Japan) and inserted between the XhoI and PmeI restriction sites in the 3'UTR of the hRluc gene in the psiCHECK-2 vector (Promega). The amplified fragment was cloned into the psiCHECK-2 vector and confirmed by sequencing using the following primers: 116-123F, GATCGCTCGAGACTC CTGTGGACTTCTTCTTCG; 116-123R, CTCTAGGTTT AAACGCGGAGAAGGGGTTAGCA; 377-384F, CGAT CGCTCGAGTCTGGCACCTCTTTCTTCTGA; 377-384R, GGCCGCTCTAGGTTTAAACGACATGTGCCCAGCTCT CCT; 729-735F, GATCGCTCGAGCTGCACGTTCTGCCA AGGT; 729-735R, GCTCTAGGTTTAAACGGACGCCT CCAGCAATAATA; 1140-1147F, GATCGCTCGAGCTCT GGGTGTCTTGGTCTT; and 1140-1147R, CGCTCTAGG TTTAAACGGGGCTGCAGACTGAGTTAT.
PC3 cells were then transfected with 5 ng vector, 10 nM mature miRNA molecules, Pre-miRNA™ miR-145 (Applied Biosystems), and 1 μl Lipofectamine 2000 (Invitrogen) in 100 μl Opti-MEM™. Firefly and Renilla luciferase activities in cell lysates were determined using a dual-luciferase assay system (Promega). Normalized data were calculated as the quotient of Renilla/firefly luciferase activities.
Small interfering (si)RNA treatment. After co-transfecting 10 nM small interfering RNA si-FSCN1 (J-019576-08; Thermo Fisher Scientific, Waltham, MA, USA) or negativecontrol siRNA (D-001810-10; Thermo Fisher Scientific), PC cells were seeded into 96-well plates at 3x10 3 cells per well. After 72 h, cell proliferation, cell migration and cell invasion assays were performed. Triplicate wells were measured for cell viability in each treatment group.
Statistical analysis. The relationships between two groups and the numerical values obtained by real-time RT-PCR were analyzed using the non-parametric Mann-Whitney U test. Expert StatView (version 4, SAS Institute Inc., Cary, NC, USA) analysis software was used, and statistical significance was defined as a p-value of <0.05.
Results

Effect of miR-145 transfection on cell proliferation in PC cell
lines. We first examined the expression levels of miR-145 in PC cell lines compared to normal prostate tissues. The expression levels of miR-145 were extremely low in both the PC cell lines, PC3 and DU145, compared to the normal prostate tissues (Fig. 1A) , suggesting that the endogenous miR-145 in those cell lines does not affect cell viability. Therefore, we performed gain-of-function studies using mature miR-145. The XTT cell proliferation assay showed significant cell growth inhibition in miR-145 transfectants in both the PC3 and DU145 cells compared to the control transfectants (PC3, 32.5% of control, p<0.01; DU145, 62.8% of control, p<0.01) (Fig. 1B) . The remarkable cell growth inhibition was particularly evident in PC3 cells.
Identification of miR-145 target genes by genome-wide gene expression analysis.
In order to investigate the molecular basis of miR-145 tumor suppression in PC cells, we examined the effect of miR-145 on protein-coding genes. Mature miR-145 was transiently transfected into PC3 and DU145 cells, with negative-miRNA transfection used as the control. Comprehensive gene expression analysis (see Materials and methods) clearly showed changes in gene expression patterns between miR-145 and negative-control transfectants. In order to identify candidate miR-145 target genes, a cut-off value of <-1.00-fold was applied to the array data. This filtering resulted in the identification of 20 genes that were significantly down-regulated upon miR-145 transfection in both the PC3 and DU145 cells (Table I ). The 3'UTR regions of these down-regulated genes were examined for miR-145 target sites using the TargetScan database (release 5.1, http://www.targetscan.org/). Of the top 20 putative gene targets, 12 genes contained miR-145 target sites (Table I) .
FSCN1 as a target of post-transcriptional repression by miR-145.
We focused on FSCN1 as it was listed as the top candidate gene for miR-145 in the genome-wide gene expression analysis. The expression level of FSCN1 mRNA was significantly decreased by miR-145 transfection in both Table I . Top 20 genes that were down-regulated by >0.5-fold in miR-145-transfected PC3 and DU145 cells in comparison to the control. PC cell lines (Fig. 2A) . The protein expression level of FSCN1 was also markedly reduced in the PC cell lines after miR-145 transfection (Fig. 2B) .
-----------------------------------------------------------------------------------------------------
PC3 cells were used to determine whether the suppression of miR-145 affected FSCN1 expression. The TargetScan database (release 5.1, http://www.targetscan.org/) showed that four conserved sites were expected in the 3'UTR of FSCN1 (Fig. 3, upper panel) . The luciferase reporter assay confirmed that the 3'UTR of FSCN1 contained actual targets of miR-145. Specifically, luciferase activity was significantly decreased at two of the four predicted sites (positions 377-383 and 1140-1146 in the 3'UTR of FSCN1) (Fig. 3, lower panel) .
Effect of FSCN1 knockdown on cell proliferation, migration and invasion activities in PC cell lines.
We examined the expression levels of FSCN1 in PC cell lines, using normal prostate tissues as the controls. The mRNA expression levels of FSCN1 were determined by quantitative real-time RT-PCR analysis. The expression levels of FSCN1 in the PC3 and DU145 cells were markedly higher than in the normal tissues (Fig. 4A) . A loss-of-function assay using siRNA analysis was performed to examine the oncogenic function of FSCN1 that was directly targeted by miR-145. We investigated whether si-FSCN1 reduced both mRNA and protein expression levels in PC3 and DU145 transfectants. After a 72-h transfection, FSCN1 mRNA and FSCN1 protein were successfully reduced by si-FSCN1 (Fig. 4B and C) .
The XTT assay revealed significant cell growth inhibition in si-FSCN1 transfectants (Fig. 5A) . The wound healing assay (measuring % of wound closure) demonstrated that si-FSCN1 inhibited cell migration in PC3 (60.3±3.2 of the control) and DU145 (74.1±1.7 of the control) (Fig. 5B) . The Matrigel invasion assay showed that the number of invading cells was significantly decreased in both si-FSCN1 transfectants: PC3 (invading cell numbers: Control, 28.5±6.2; si-FSCN1, 15.8±2.3) and DU145 (control, 64.6±9; si-FSCN1, 1.4±0.3) (Fig. 5C ).
Discussion
Treatments available for organ-confined PC include radical prostatectomy, irradiation, or hormonal therapy. A subset of PC patients is prone to disease relapse and metastasis, which frequently progresses to advanced disease even after surgery and can be the cause of death. Therefore, a number of alternative ways for controlling PC have emerged. Expression signatures have shown that miRNAs are dysregulated in a wide variety of human cancers. The fact that miRNAs function as either oncogenes or tumor suppressors has generated great interest in their possible use as novel targets or tools for anticancer therapies.
Many studies have been carried out to identify differentially expressed miRNAs in PC based on genome-wide miRNA expression profiling (9, (11) (12) (13) (14) (15) (16) . Using micro-dissected malignant and uninvolved areas from 40 prostatectomy specimens, five miRNAs (miR-23b, miR-100, miR-145, miR-221 and miR-222) were found to be significantly downregulated in malignant tissues compared to normal tissues (16) . More recent data using matched tumor and adjacent normal tissues obtained from 76 patients identified 15 differentially expressed miRNAs: miR -16, miR-31, miR-125b, miR-145, miR-149, miR-181b, miR-184, miR-205, miR-221 and miR-222 were down-regulated, whereas miR-96, miR-182, miR-182*, miR-183 and miR-375 were up-regulated (15) . In comparative miRNA expression studies, several important miRNAs, such as miR-145, in PC initiation, development and metastasis, have been identified.
Recently, the down-regulation of miR-145 in different types of tumors suggests its role in controlling cell proliferation, migration and invasion (23) . The first report of tumor suppression by miR-145 came from studies on colon cancer and demonstrated that miR-145 inhibited cell growth by targeting insulin receptor substrate 1 (27) . miR-145 can also impact cell migration and invasion. Using the expression profile of miR-145 in different metastatic breast cancer cell lines, it was evident that cell invasion was reduced by the miR-145-mediated suppression of the metastasis gene mucin1 (28) . It has been reported that the lower expression of miR-145 is due to the methylation of the promoter region of miR-145 in PC cell lines and clinical samples. The overexpression of miR-145 in the PC cell lines, PC3 and DU145, induced apoptosis. Target gene searches have revealed that the pro-apoptotic gene, TNFSF10, is significantly upregulated by the overexpression of miR-145 (17) .
We have identified novel pathways of miR-145-mediated suppression of tumor cell invasion and migration in many cancers based on genome-wide gene expression profiles (18, 21) . In this study, we determined that miR-145 regulates mRNAs in PC cells using gene expression profiling. In our search for miR-145 target genes in PC cells, FSCN1 was the most down-regulated gene. The miR-145 target gene profile of PC cells is in complete accord with our own data on bladder cancer and esophageal cancer cell profiles (18, 21) . Our results strongly indicate that FSCN1 is a target gene of miR-145 and suggest its important role as an oncogene in human cancer cells.
FSCN1 is an actin-binding protein required for the formation of actin-based cell surface protrusions and cytoplasmic bundles of microfilaments (29) . FSCN1 activity is essential for filopodial dynamics, and it has been proposed that fascin imparts rigidity to the forming filopodia to efficiently push the membrane forward (30) . Cells with prominent cytoplasmic protrusions as well as actively migrating cells express high levels of FSCN1, whereas this protein is undetectable in most normal epithelial cells (31) .
The overexpression of FSCN1 in tumors of the lung (31), prostate (32) , esophagus (33) , breast (34) , colon (35) , pancreas (36) , ovary (37) and skin (38) usually correlates with high grade, extensive invasion, distant metastasis and poor prognosis. We demonstrate that the silencing of the FSCN1 gene in PC3 and DU145 cells decreases cell motility and invasion. Similarly, studies have also shown that FSCN1 inhibition reduces tumor growth and lymph node metastasis in DU145 cells in mice. In addition, FSCN1 epithelial expression was significantly up-regulated in localized and hormone-refractory PC compared to benign prostate tissue (32) . These results show that the overexpression of FSCN1 contributes to PC progression and is a potential therapeutic target for this disease.
In summary, our expression profiles in PC cell lines show that FSCN1 can have an oncogenic function and that miR-145 can act as a tumor suppressor through the direct control of FSCN1 expression. The overexpression of FSCN1 contributes to cell migration and invasion in various cancer cells. As the down-regulation of miR-145 and the overexpression of FSCN1 have been commonly identified in many types of cancer, including PC, we suggest that this tumor suppressive miRNA and oncogenic mRNA pathway could be an important therapeutic target in human cancers.
